IL6 and neoplasm: Consistent with the rescue of tumor growth and osteoclast activation by JAK2 inhibitor, also the HFD-induced elevation of bone marrow CD11b+Ly6C+Ly6Gint cells and systemic IL-6 levels were abolished (Figures 6D-6E and data not shown).